RE:RE:Equity raise or LoCYes, Tom I did ask myself that question many times. The answer I settled with for peace of mind was that Pli never did a placebo controlled Phase 2 study and thus Big Pharma refused to come together. A deal was very close with Boehringers but it fell apart at the last minute when one of the family members insisted on one condition which PL couldn’t accept.
The only reason I am still around is that I do expect LMNl to deliver on Ryplazim and get regulatory approval of the plasma protein by the FDA and in Canada and Europe. The company has clearly stated that it will not develop other acute applications of Ryplazim nor wound healing applications. This is sad. Rather the intent is just to sell the platform as soon as it can and focus attention and resources on the small molecule division.
While I was hoping that Ryplazim Bla would have been filed by now and a marketing deal signed, the company is once again caught in a cash crunch in a Covid uncertain world. If the Bla is not refiled soon and a marketing deal signed, further dilution will occur via a Nasdaq listing or selling off a portion of the company to another private invest. Enlarging the LoC to $80-100M isn’t going to work given past history.
So I am sitting back and waiting to see just what happens to the Ryplazim asset. Will I hang around to see what small molecule platform will bring? Not sure, frankly. If favourable 4050 Phase 2 placebo controlled clinical trial results are obtained before Ryplazim is sold off, I may stick around to see what happens. For the moment my focus is on Ryplazim and I just hope the company can get FDAapproval without having to suffer further significant dilution.